New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication

International Journal of Cell Biology

Volumn , Issue , 2013, Pages

  Gunter, Jennifer H ^a   Sarkar, Phoebe L ^a   Lubik, Amy A ^a,b   Nelson, Colleen C ^a,b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; TETRAHYDROLIPSTATIN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BODY MASS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; HUMAN; HYPERINSULINEMIA; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

EID: 84876514140     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2013/834684     Document Type: Review

References (186)

1. WHO, Obesity and Overweight. Fact Sheet #311, 2012, http://www.who.int/ mediacentre/factsheets/fs311/en/
2. Malnick S. D. H., Knobler H., The medical complications of obesity. Oxford Journals: Medicine 2006 99 9 565 579 2-s2.0-33749616411 10.1093/qjmed/hcl085 (Pubitemid 44540533)
3. Bergstrm A., Pisani P., Tenet V., Wolk A., Adami H. O., Overweight as an avoidable cause of cancer in Europe. International Journal of Cancer 2001 91 3 421 430 10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T (Pubitemid 32049639)
4. Beral V., Hermon C., Peto R., Reeves G., Brinton L., Marchbanks P., Negri E., Ness R., Peeters P. H. M., Vessey M., Calle E. E., Gapstur S. M., Patel A. V., Maso L. D., Talamini R., Chetrit A., Hirsh-Yechezkel G., Lubin F., Sadetzki S., Allen N., Beral V., Bull D., Callaghan K., Crossley B., Gaitskell K., Goodill A., Green J., Hermon C., Key T., Moser K., Reeves G., Collins R., Doll R., Peto R., Gonzalez C. A., Lee N., Marchbanks P., Ory H. W., Peterson H. B., Wingo P. A., Martin N., Pardthaisong T., Silpisornkosol S., Theetranont C., Boosiri B., Chutivongse S., Jimakorn P., Virutamasen P., Wongsrichanalai C., Tjonneland A., Titus-Ernstoff L., Byers T., Rohan T., Mosgaard B. J., Vessey M., Yeates D., Freudenheim J. L., Chang-Claude J., Kaaks R., Anderson K. E., Folsom A., Robien K., Rossing M. A., Thomas D. B., Weiss N. S., Riboli E., Clavel-Chapelon F., Cramer D., Hankinson S. E., Tworoger S. S., Franceschi S., La Vecchia C., Negri E., Magnusson C., Riman T., Weiderpass E., Wolk A., Schouten L. J., van den Brandt P. A., Chantarakul N., Koetsawang S., Rachawat D., Palli D., Black A., Berrington de Gonzalez A., Brinton L. A., Freedman D. M., Hartge P., Hsing A. W., Lacey Jr. J. V., Hoover R. N., Schairer C., Graff-Iversen S., Selmer R., Bain C. J., Green A. C., Purdie D. M., Siskind V., Webb P. M., Mccann S. E., Hannaford P., Kay C., Binns C. W., Lee A. H., Zhang M., Ness R. B., Nasca P., Coogan P. F., Palmer J. R., Rosenberg L., Kelsey J., Paffenbarger R., Whittemore A., Katsouyanni K., Trichopoulou A., Trichopoulos D., Tzonou A., Dabancens A., Martinez L., Molina R., Salas O., Goodman M. T., Lurie G., Carney M. E., Wilkens L. R., Hartman L., Manjer J., Olsson H., Grisso J. A., Morgan M., Wheeler J. E., Peeters P. H. M., Casagrande J., Pike M. C., Ross R. K., Wu A. H., Miller A. B., Kumle M., Lund E., Mcgowan L., Shu X. O., Zheng W., Farley T. M. M., Holck S., Meirik O., Risch H. A., Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Medicine 2012 9 4 e1001200 10.1371/journal.pmed.1001200
5. Chromecki T. F., Cha E. K., Fajkovic H., Rink M., Ehdaie B., Svatek R. S., Karakiewicz P. I., Lotan Y., Tilki D., Bastian P. J., Kassouf W., Durand M., Novara G., Fritsche H.-M., Burger M., Izawa J. I., Brisuda A., Babjuk M., Pummer K., Shariat S. F., Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU International 2012 111 2 249 255 10.1111/j.1464-410X.2012.11322.x
6. Navai N., Wood C. G., Environmental and modifiable risk factors in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2012 30 2 220 224 10.1016/j.urolonc.2011.10.001
7. MacInnis R. J., English D. R., Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes and Control 2006 17 8 989 1003 2-s2.0-33747883049 10.1007/s10552-006-0049-z (Pubitemid 44290764)
8. Rodriguez C., Freedland S. J., Deka A., Jacobs E. J., McCullough M. L., Patel A. V., Thun M. J., Calle E. E., Body mass index, weight change, and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiology Biomarkers and Prevention 2007 16 1 63 69 10.1158/1055-9965.EPI-06- 0754 (Pubitemid 46174265)
9. Fowke J. H., Motley S. S., Barocas D. A., Cookson M. S., Concepcion R., Byerly S., Smith J. A., The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes and Control 2011 22 3 417 426 2-s2.0-79955761349 10.1007/s10552-010-9713-4
10. Rickles A. S., Iannuzzi J. C., Mironov O., Deeb A. P., Sharma A., Fleming F. J., Monson J. R., Visceral obesity and colorectal cancer: are we missing the boat with BMI? Journal of Gastrointestinal Surgery 2013 17 1 133 143 10.1007/s11605-012-2045-9
11. Hammarsten J., Peeker R., Urological aspects of the metabolic syndrome. Nature Reviews Urology 2011 8 9 483 494 10.1038/nrurol.2011.112
12. Porter M. P., Stanford J. L., Obesity and the risk of prostate cancer. The Prostate 2005 62 4 316 321 2-s2.0-13544267779 10.1002/pros.20121 (Pubitemid 40224137)
13. Carmichael A. R., Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG: An International Journal of Obstetrics and Gynaecology 2006 113 10 1160 1166 2-s2.0-33748755434 10.1111/j.1471-0528.2006. 01021.x (Pubitemid 44401209)
14. Calle E. E., Rodriguez C., Walker-Thurmond K., Thun M. J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. The New England Journal of Medicine 2003 348 17 1625 1638 2-s2.0-0037464510 10.1056/NEJMoa021423 (Pubitemid 36459468)
15. Ma J., Li H., Giovannucci E., Mucci L., Qiu W., Nguyen P. L., Gaziano J. M., Pollak M., Stampfer M. J., Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. The Lancet Oncology 2008 9 11 1039 1047 2-s2.0-54349083481 10.1016/S1470-2045(08)70235-3
16. Fowke J. H., Matthews C. M., Buchowski M. S., Signorello L. B., Chang S. S., Cookson M. S., Blot W. J., Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer and Prostatic Diseases 2008 11 3 264 269 2-s2.0-50649085199 10.1038/sj.pcan.4501022
17. Jayachandran J., Aronson W. J., Terris M. K., Presti J. C., Amling C. L., Kane C. J., Freedland S. J., Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the shared equal access regional cancer hospital database. BJU International 2008 102 8 964 968 2-s2.0-52649084792 10.1111/j.1464-410X.2008.07881.x
18. Rodriguez C., Patel A. V., Calle E. E., Jacobs E. J., Chao A., Thun M. J., Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiology Biomarkers and Prevention 2001 10 4 345 353 2-s2.0-0034899087 (Pubitemid 32703219)
19. Gilbert C. A., Slingerland J. M., Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annual Review of Medicine 2013 64 45 57 10.1146/annurev-med-121211-091527
20. Hursting S. D., Berger N. A., Energy balance, host-related factors, and cancer progression. Journal of Clinical Oncology 2010 28 26 4058 4065 2-s2.0-77956917907 10.1200/JCO.2010.27.9935
21. Iyer A., Fairlie D. P., Prins J. B., Hammock B. D., Brown L., Inflammatory lipid mediators in adipocyte function and obesity. Nature Reviews Endocrinology 2010 6 2 71 82 2-s2.0-76149111947 10.1038/nrendo.2009.264
22. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I., Increased oxidative stress in obesity and its impact on metabolic syndrome. Journal of Clinical Investigation 2004 114 12 1752 1761 2-s2.0-15244342531 10.1172/JCI200421625 (Pubitemid 40385531)
23. de Luca C., Olefsky J. M., Inflammation and insulin resistance. The FEBS Letters 2008 582 1 97 105 2-s2.0-37549022688 10.1016/j.febslet.2007.11.057 (Pubitemid 50010731)
24. Das U. N., Essential fatty acids enhance free radical generation and lipid peroxidation to induce apoptosis of tumor cells. Clinical Lipidology 2011 6 4 463 489 10.2217/clp.11.34
25. Nomura D. K., Lombardi D. P., Chang J. W., Niessen S., Ward A. M., Long J. Z., Hoover H. H., Cravatt B. F., Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chemistry and Biology 2011 18 7 846 856 2-s2.0-79960939546 10.1016/j.chembiol. 2011.05.009
26. Cathcart M.-C., Lysaght J., Pidgeon G. P., Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer and Metastasis Reviews 2011 30 3-4 363 385 10.1007/s10555-011-9324-x
27. Locke J. A., Tomlinson Guns E. S., Lehman M. L., Ettinger S., Zoubeidi A., Lubik A., Margiotti K., Fazli L., Adomat H., Wasan K. M., Gleave M. E., Nelson C. C., Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. The Prostate 2010 70 3 239 251 2-s2.0-75649143344 10.1002/pros.21057
28. Ahima R., Osei S., Adipokines in obesity. Frontiers of Hormone Research 2007 36 182 197 2-s2.0-43049128930 10.1159/000115365
29. Hursting S. D., DiGiovanni J., Dannenberg A. J., Azrad M., LeRoith D., Demark-Wahnefried W., Kakarala M., Brodie A., Berger N. A., Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prevention Research 2012 5 11 1260 1272 10.1158/1940-6207.CAPR-12-0140
30. Arditi J. D., Venihaki M., Karalis K. P., Chrousos G. P., Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Hormone and Metabolic Research 2007 39 1 9 13 2-s2.0-33947589720 10.1055/s-2007-956518 (Pubitemid 46535150)
31. Cox M. E., Gleave M. E., Zakikhani M., Bell R. H., Piura E., Vickers E., Cunningham M., Larsson O., Fazli L., Pollak M., Insulin receptor expression by human prostate cancers. The Prostate 2009 69 1 33 40 2-s2.0-58149339692 10.1002/pros.20852
32. Isbarn H., Boccon-Gibod L., Carroll P. R., Montorsi F., Schulman C., Smith M. R., Sternberg C. N., Studer U. E., Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. European Urology 2009 55 1 62 75 2-s2.0-56249127471 10.1016/j.eururo.2008.10.008
33. Sahra I. B., Laurent K., Loubat A., Giorgetti-Peraldi S., Colosetti P., Auberger P., Tanti J. F., Le Marchand-Brustel Y., Bost F., The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008 27 25 3576 3586 2-s2.0-44849099894 10.1038/sj.onc.1211024 (Pubitemid 351793803)
34. Smith M. R., Lee H., Nathan D. M., Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism 2006 91 4 1305 1308 2-s2.0-33646029746 10.1210/jc.2005-2507
35. Hammarsten J., Högstedt B., Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. European Journal of Cancer 2005 41 18 2887 2895 2-s2.0-28244481524 10.1016/j.ejca.2005.09.003 (Pubitemid 41713128)
36. Neuhouser M. L., Till C., Kristal A., Goodman P., Hoque A., Platz E. A., Hsing A. W., Albanes D., Parnes H. L., Pollak M., Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prevention Research 2010 3 3 279 289 10.1158/1940-6207.CAPR-09-0188
37. Ulanet D. B., Ludwig D. L., Kahn C. R., Hanahan D., Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proceedings of the National Academy of Sciences of the United States of America 2010 107 24 10791 10798 2-s2.0-77953973648 10.1073/pnas.0914076107
38. Zhang H., Fagan D. H., Zeng X., Freeman K. T., Sachdev D., Yee D., Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010 29 17 2517 2527 2-s2.0-77951879658 10.1038/onc.2010.17
39. Seim I., Lubik A. L., Lehman M., Tomlinson N., Whiteside E. J., Herington A., Nelson C., Chopin L., Cloning of a novel insulin-regulated ghrelin transcript in prostate cancer. Journal of Molecular Endocrinology 2012 10.1530/JME-12-0150
40. Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R., Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine Reviews 2009 30 6 586 623 2-s2.0-70849120946 10.1210/er.2008-0047
41. del Barco S., Vazquez-Martin A., Cufí S., Oliveras-Ferraros C., Bosch-Barrera J., Joven J., Martin-Castillo B., Menendez J. A., Metformin: multi-faceted protection against cancer. Oncotarget 2011 2 12 896 917
42. Heni M., Hennenlotter J., Scharpf M., Lutz S. Z., Schwentner C., Todenhöfer T., Schilling D., Machicao F., Staiger H., Häring H.-U., Stenzl A., Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer. PLoS ONE 2012 7 12 e50953 10.1371/journal.pone.0050953
43. Call R., Grimsley M., Cadwallader L., Cialone L., Hill M., Hreish V., Travis King S., Riche D. M., Insulin-carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgraduate Medicine 2010 122 3 158 165 2-s2.0-77953116995 10.3810/pgm.2010.05.2153
44. Stein K. B., Snyder C. F., Barone B. B., Yeh H. C., Peairs K. S., Derr R. L., Wolff A. C., Brancati F. L., Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Digestive Diseases and Sciences 2010 55 7 1839 1851 2-s2.0-77954405226 10.1007/s10620-009-0944-8
45. Simon D., Balkau B., Diabetes mellitus, hyperglycaemia and cancer. Diabetes and Metabolism 2010 36 3 182 191 2-s2.0-77953480614 10.1016/j.diabet.2010.04.001
46. Fukui M., Tanaka M., Kadono M., Imai S., Hasegawa G., Yoshikawa T., Nakamura N., Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 2008 31 5 930 931 2-s2.0-48649095772 10.2337/dc07-1962
47. Pierce B. L., Plymate S., Ostrander E. A., Stanford J. L., Diabetes mellitus and prostate cancer risk. The Prostate 2008 68 10 1126 1132 2-s2.0-45749116179 10.1002/pros.20777 (Pubitemid 351875184)
48. Abdollah F., Briganti A., Suardi N., Gallina A., Capitanio U., Salonia A., Cestari A., Guazzoni G., Rigatti P., Montorsi F., Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy. Prostate Cancer and Prostatic Diseases 2011 14 1 74 78 2-s2.0-79951678833 10.1038/pcan.2010.41
49. Wallner L. P., Morgenstern H., McGree M. E., Jacobson D. J., Sauver J. L. S., Jacobsen S. J., Sarma A. V., The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the olmsted county study. Urology 2011 77 1 137 141 2-s2.0-78650857644 10.1016/j.urology.2010.07.516
50. Snyder C. F., Stein K. B., Barone B. B., Peairs K. S., Yeh H. C., Derr R. L., Wolff A. C., Carducci M. A., Brancati F. L., Does pre-existing diabetes affect prostate cancer prognosis A systematic review. Prostate Cancer and Prostatic Diseases 2010 13 1 58 64 2-s2.0-76949099436 10.1038/pcan.2009.39
51. Kasper J. S., Giovannucci E., A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiology Biomarkers and Prevention 2006 15 11 2056 2062 2-s2.0-33845328853 10.1158/1055-9965.EPI-06-0410 (Pubitemid 44877026)
52. Daousi C., Casson I. F., Gill G. V., MacFarlane I. A., Wilding J. P. H., Pinkney J. H., Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgraduate Medical Journal 2006 82 966 280 284 2-s2.0-33645924034 10.1136/pmj.2005.039032
53. Currie C. J., Poole C. D., Gale E. A. M., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009 52 9 1766 1777 2-s2.0-68449094325 10.1007/s00125-009-1440-6
54. Jonasson J. M., Ljung R., Talbäck M., Haglund B., Gudbjörnsdòttir S., Steineck G., Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009 52 9 1745 1754 2-s2.0-68449104625 10.1007/s00125-009-1444-2
55. Hemkens L. G., Grouven U., Bender R., Günster C., Gutschmidt S., Selke G. W., Sawicki P. T., Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009 52 9 1732 1744 2-s2.0-68449104156 10.1007/s00125-009-1418-4
56. Bowker S. L., Majumdar S. R., Veugelers P., Johnson J. A., Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006 29 2 254 258 2-s2.0-33645766204 (Pubitemid 44106500)
57. Evans J. M. M., Donnelly L. A., Emslie-Smith A. M., Alessi D. R., Morris A. D., Metformin and reduced risk of cancer in diabetic patients. The British Medical Journal 2005 330 7503 1304 1305 2-s2.0-20444461067 10.1136/bmj.38415. 708634.F7 (Pubitemid 40813563)
58. Landman G. W. D., Kleefstra N., van Hateren K. J. J., Groenier K. H., Gans R. O. B., Bilo H. J. G., Metformin associated with lower cancer mortality in type 2 diabetes: zodiac-16. Diabetes Care 2010 33 2 322 326 2-s2.0-75149179169 10.2337/dc09-1380
59. He X. X., Tu S. M., Lee M. H., Yeung S. C. J., Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Annals of Oncology 2011 22 12 2640 2645 10.1093/annonc/mdr020
60. Cauley J. A., McTiernan A., Rodabough R. J., LaCroix A., Bauer D. C., Margolis K. L., Paskett E. D., Vitolins M. Z., Furberg C. D., Chlebowski R. T., Alving B., Rossouw J., Pottern L., Prentice R., Anderson G., Kooperberg C. L., Patterson R. E., Shumaker S., Stein E., Cummings S., Wassertheil-Smoller S., Hays J., Manson J., Assaf A. R., Phillips L., Beresford S., Hsia J., Whitlock E., Caan B., Kochen J. M., Howard B. V., Van Horn L., Black H., Stefanick M. L., Lane D., Jackson R., Lewis C. E., Bassford T., Wactawski-Wende J., Robbins J., Hubbell A., Judd H., Langer R. D., Gass M., Limacher M., Curb D., Wallace R., Ockene J., Lasser N., O'Sullivan M. J., Brunner R., Heiss G., Kuller L., Johnson K. C., Brzyski R., Sarto G. E., Bonds D., Hendrix S., Statin use and breast cancer: prospective results from the women's health initiative. Journal of the National Cancer Institute 2006 98 10 700 707 10.1093/jnci/djj188 (Pubitemid 43821787)
61. Karp I., Behlouli H., LeLorier J., Pilote L., Statins and cancer risk. The American Journal of Medicine 2008 121 4 302 309 2-s2.0-40949094769 10.1016/j.amjmed.2007.12.011 (Pubitemid 351417853)
62. Algire C., Amrein L., Zakikhani M., Panasci L., Pollak M., Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocrine-Related Cancer 2010 17 2 351 360 2-s2.0-77953589054 10.1677/ERC-09-0252
63. DeCensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., Gandini S., Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research 2010 3 11 1451 1461 2-s2.0-78649302320 10.1158/1940-6207.CAPR-10-0157
64. Wright J. L., Stanford J. L., Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes and Control 2009 20 9 1617 1622 2-s2.0-70350583054 10.1007/s10552-009-9407-y
65. Dowling R. J. O., Zakikhani M., Fantus I. G., Pollak M., Sonenberg N., Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research 2007 67 22 10804 10812 2-s2.0-36348950449 10.1158/0008-5472.CAN-07-2310 (Pubitemid 350145909)
66. Green A. S., Chapuis N., Maciel T. T., Willems L., Lambert M., Arnoult C., Boyer O., Bardet V., Park S., Foretz M., Viollet B., Ifrah N., Dreyfus F., Hermine O., Moura I. C., Lacombe C., Mayeux P., Bouscary D., Tamburini J., The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010 116 20 4262 4273 2-s2.0-78549283186 10.1182/blood-2010-02-269837
67. Tao R., Gong J., Luo X., Zang M., Guo W., Wen R., Luo Z., AMPK exerts dual regulatory effects on the PI3K pathway. Journal of Molecular Signaling 2010 5 1, article 1 2-s2.0-77949459392 10.1186/1750-2187-5-1
68. Larsson O., Morita M., Topisirovic I., Alain T., Blouin M.-J., Pollak M., Sonenberg N., Distinct perturbation of the translatome by the antidiabetic drug metformin. Proceedings of the National Academy of Sciences of the United States of America 2012 109 23 8977 8982 10.1073/pnas.1201689109
69. Oliveras-Ferraros C., Vazquez-Martin A., Menendez J. A., Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle 2009 8 10 1633 1636 2-s2.0-66849093704
70. Swinnen J. V., Heemers H., van de Sande T., de Schrijver E., Brusselmans K., Heyns W., Verhoeven G., Androgens, lipogenesis and prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 2004 92 4 273 279 2-s2.0-12344287240 10.1016/j.jsbmb.2004.10.013 (Pubitemid 40128248)
71. Samarajeewa N. U., Ham S., Yang F., Simpson E. R., Brown K. A., Promoter-specific effects of metformin on aromatase transcript expression. Steroids 2011 76 8 768 771 2-s2.0-79958756136 10.1016/j.steroids.2011.02.041
72. Wu B., Li S., Sheng L., Zhu J., Gu L., Shen H., La D., Hambly B. D., Bao S., Di W., Metformin inhibits the development and metastasis of ovarian cancer. Oncology Reports 2012 28 3 903 908 10.3892/or.2012.1890
73. Li W., Yuan Y., Huang L., Qiao M., Zhang Y., Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Research and Clinical Practice 2012 96 2 187 195 10.1016/j.diabres.2011.12.028
74. Bao B., Wang Z., Ali S., Ahmad A., Azmi A. S., Sarkar S. H., Banerjee S., Kong D., Li Y., Thakur S., Sarkar F. H., Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prevention Research 2012 5 3 355 364 10.1158/1940-6207.CAPR-11-0299
75. Hadad S. M., Fleming S., Thompson A. M., Targeting AMPK: a new therapeutic opportunity in breast cancer. Critical Reviews in Oncology/Hematology 2008 67 1 1 7 2-s2.0-44649104448 10.1016/j.critrevonc.2008. 01.007
76. Pollak M., Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prevention Research 2010 3 9 1060 1065 2-s2.0-77956401999 10.1158/1940-6207.CAPR-10-0175
77. Derosa G., Cicero A. F. G., D'Angelo A., Fogari E., Maffioli P., Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics 2012 37 2 187 195 2-s2.0-79961100303 10.1111/j.1365-2710.2011. 01280.x
78. + breast cancer. Annals of the New York Academy of Sciences 2010 1210 86 92 2-s2.0-78349257052 10.1111/j.1749-6632.2010.05777.x
79. Tomek K., Wagner R., Varga F., Singer C. F., Karlic H., Grunt T. W., Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Molecular Cancer Research 2011 9 12 1767 1779 10.1158/1541-7786.MCR-10-0467
80. Mansour M., Schwartz D., Judd R., Akingbemi B., Braden T., Morrison E., Dennis J., Bartol F., Hazi A., Napier I., Abdel-Mageed A. B., Thiazolidinediones/PPAR γ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. International Journal of Oncology 2011 38 2 537 546 2-s2.0-78651234318 10.3892/ijo.2010.877
81. Kridel S. J., Axelrod F., Rozenkrantz N., Smith J. W., Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Research 2004 64 6 2070 2075 2-s2.0-1542720382 10.1158/0008-5472.CAN-03-3645 (Pubitemid 38339455)
82. Knowles L. M., Yang C., Osterman A., Smith J. W., Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. The Journal of Biological Chemistry 2008 283 46 31378 31384 2-s2.0-57649128306 10.1074/jbc.M803384200
83. Fujiwara J., Sowa Y., Horinaka M., Koyama M., Wakada M., Miki T., Sakai T., The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells. International Journal of Oncology 2012 40 5 1483 1491 10.3892/ijo.2012.1353
84. Little J. L., Wheeler F. B., Fels D. R., Koumenis C., Kridel S. J., Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Research 2007 67 3 1262 1269 2-s2.0-33847034466 10.1158/0008-5472.CAN-06-1794
85. Browning D. R. L., Martin R. M., Statins and risk of cancer: a systematic review and metaanalysis. International Journal of Cancer 2007 120 4 833 843 2-s2.0-33846604584 10.1002/ijc.22366 (Pubitemid 46175404)
86. Hamilton R. J., Banez L. L., Aronson W. J., Terris M. K., Platz E. A., Kane C. J., Presti J. C., Amling C. L., Freedland S. J., Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the shared equal access regional cancer hospital (SEARCH) database. Cancer 2010 116 14 3389 3398 2-s2.0-77954906436 10.1002/cncr.25308
87. Shafique K., McLoone P., Qureshi K., Leung H., Hart C., Morrison D. S., Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up. BMC Cancer 2012 12 article 25 10.1186/1471-2407-12-25
88. Loeb S., Kan D., Helfand B. T., Nadler R. B., Catalona W. J., Is statin use associated with prostate cancer aggressiveness? BJU International 2010 105 9 1222 1225 2-s2.0-77950799056 10.1111/j.1464-410X.2009.09007.x
89. Mostaghel E. A., Solomon K. R., Pelton K., Freeman M. R., Montgomery R. B., Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS ONE 2012 7 1 e30062 10.1371/journal. pone.0030062
90. Yu O., Boudreau D. M., Buist D. S. M., Miglioretti D. L., Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes and Control 2009 20 5 609 616 2-s2.0-67349221748 10.1007/s10552-008-9271-1
91. Segawa Y., Yoshimura R., Hase T., Nakatani T., Wada S., Kawahito Y., Kishimoto T., Sano H., Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. The Prostate 2002 51 2 108 116 2-s2.0-0036570532 10.1002/pros.10058 (Pubitemid 34492617)
92. Du Q., Wang Y.-J., Yang S., Wu B., Han P., Zhao Y.-Y., A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Current Medical Research and Opinion 2012 28 5 723 730 10.1185/03007995.2012.681636
93. Colmers I. N., Bowker S. L., Johnson J. A., Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes and Metabolism 2012 38 6 475 484 10.1016/j.diabet.2012.06.003
94. Bolden A., Bernard L., Jones D., Akinyeke T., Stewart L. V., The PPAR γ agonist troglitazone regulates Erk 1/2 phosphorylation via a PPAR γ -independent, MEK-dependent pathway in human prostate cancer cells. PPAR Research 2012 2012 9 929052 10.1155/2012/929052
95. Jiang M., Fernandez S., Jerome W. G., He Y., Yu X., Cai H., Boone B., Yi Y., Magnuson M. A., Roy-Burman P., Matusik R. J., Shappell S. B., Hayward S. W., Disruption of PPAR γ signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death and Differentiation 2010 17 3 469 481 2-s2.0-76749130074 10.1038/cdd.2009.148
96. Al-Alem L., Southard R. C., Kilgore M. W., Curry T. E., Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPAR γ independent manner. PLoS ONE 2011 6 1 2-s2.0-79251636617 10.1371/journal.pone.0016179 e16179
97. Kim S., Lee J. J., Heo D. S., PPAR γ ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells. Biochemical and Biophysical Research Communications 2011 406 3 389 395 2-s2.0-79952739732 10.1016/j.bbrc.2011.02.052
98. Lyles B. E., Akinyeke T. O., Moss P. E., Stewart L. V., Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPAR γ -dependent and PPAR γ -independent pathways. Cell Cycle 2009 8 2 268 277 2-s2.0-58549099485
99. Tan X. H., Dagher H., Hutton C. A., Bourke J. E., Effects of PPAR γ ligands on TGF- β 1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respiratory Research 2010 11 article 21 2-s2.0-77952469124 10.1186/1465-9921-11-21
100. Kurtzhals P., Schäffer L., Sørensen A., Kristensen C., Jonassen I., Schmid C., Trüb T., Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000 49 6 999 1005 2-s2.0-0342657181 (Pubitemid 30349423)
101. Hansen B. F., Danielsen G. M., Drejer K., Sorensen A. R., Wiberg F. C., Klein H. H., Lundemose A. G., Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochemical Journal 1996 315 1 271 279 2-s2.0-0029862845 (Pubitemid 26113562)
102. Hansen B. F., Kurtzhals P., Jensen A. B., Dejgaard A., Russell-Jones D., Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 2011 54 9 2226 2231 10.1007/s00125-011-2203-8
103. Registries, A.I.o.H.a.W.A.A.o.C., Cancer in Australia: An Overview, 2010 2010 60 Canberra, Australia AIHW Australian Institute of Health and Welfare's Cancer series
104. Tewari A., Raman J. D., Chang P., Rao S., Divine G., Menon M., Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology 2006 68 6 1268 1274 2-s2.0-33845315227 10.1016/j.urology.2006.08.1059 (Pubitemid 44880345)
105. Huggins C., Effect of orchiectomy and irradiation on cancer of the prostate. Annals of Surgery 1942 115 6 1192 1200 10.1097/00000658-194206000- 00030
106. Tolis G., Koutsilieris M., Stellos A., Metastatic prostate cancer: hormone dependency and therapeutic efficacy of GnRH analogues. Acta Endocrinologica, Supplementum 1984 107 265 22 23 2-s2.0-0021144006 (Pubitemid 14013206)
107. Hellerstedt B. A., Pienta K. J., The current state of hormonal therapy for prostate cancer. CA: A Cancer Journal for Clinicians 2002 52 3 154 179 2-s2.0-0036112592 (Pubitemid 34546107)
108. Tannock I. F., de Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., Oudard S., Théodore C., James N. D., Turesson I., Rosenthal M. A., Eisenberger M. A., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine 2004 351 15 1502 1512 2-s2.0-4744366279 10.1056/NEJMoa040720 (Pubitemid 39315317)
109. Berthold D. R., Pond G. R., Soban F., de Wit R., Eisenberger M., Tannock I. F., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of Clinical Oncology 2008 26 2 242 245 2-s2.0-38349167518 10.1200/JCO.2007.12.4008
110. de Bono J. S., Oudard S., Ozguroglu M., Hansen S., MacHiels J. P., Kocak I., Gravis G., Bodrogi I., MacKenzie M. J., Shen L., Roessner M., Gupta S., Sartor A. O., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet 2010 376 9747 1147 1154 2-s2.0-77957682309 10.1016/S0140-6736(10)61389-X
111. Small E. J., Srinivas S., The antiandrogen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995 76 8 1428 1434 10.1002/1097-0142(19951015)76:8<1428::AID- CNCR2820760820>3.0.CO;2-T
112. Small E. J., Halabi S., Dawson N. A., Stadler W. M., Rini B. I., Picus J., Gable P., Torti F. M., Kaplan E., Vogelzang N. J., Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). Journal of Clinical Oncology 2004 22 6 1025 1033 2-s2.0-1842457650 10.1200/JCO.2004.06.037 (Pubitemid 41095034)
113. Montgomery R. B., Mostaghel E. A., Vessella R., Hess D. L., Kalhorn T. F., Higano C. S., True L. D., Nelson P. S., Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 2008 68 11 4447 4454 2-s2.0-49249119358 10.1158/0008-5472.CAN-08-0249
114. Taplin M. E., Bubley G. J., Shuster T. D., Frantz M. E., Spooner A. E., Ogata G. K., Keer H. N., Balk S. P., Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. The New England Journal of Medicine 1995 332 21 1393 1398 2-s2.0-0029011116 10.1056/NEJM199505253322101
115. Buchanan G., Yang M., Cheong A., Harris J. M., Irvine R. A., Lambert P. F., Moore N. L., Raynor M., Neufing P. J., Coetzee G. A., Tilley W. D., Structural and functional consequences of glutamine tract variation in the androgen receptor. Human Molecular Genetics 2004 13 16 1677 1692 2-s2.0-4444288439 10.1093/hmg/ddh181 (Pubitemid 39173438)
116. Veldscholte J., Ris-Stalpers C., Kuiper G. G. J. M., Jenster G., Berrevoets C., Claassen E., Van Rooij H. C. J., Trapman J., Brinkmann A. O., Mulder E., A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications 1990 173 2 534 540 2-s2.0-0025644325 10.1016/S0006-291X(05)80067-1
117. Dehm S. M., Schmidt L. J., Heemers H. V., Vessella R. L., Tindall D. J., Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 2008 68 13 5469 5477 2-s2.0-48549089747 10.1158/0008-5472.CAN-08-0594
118. Chen C. D., Welsbie D. S., Tran C., Baek S. H., Chen R., Vessella R., Rosenfeld M. G., Sawyers C. L., Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004 10 1 33 39 2-s2.0-1842612441 10.1038/nm972 (Pubitemid 38524696)
119. Dehm S. M., Tindall D. J., Androgen receptor structural and functional elements: role and regulation in prostate cancer. Molecular Endocrinology 2007 21 12 2855 2863 2-s2.0-36249030631 10.1210/me.2007-0223 (Pubitemid 350223500)
120. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., Reuter V., Gerald W. L., Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. American Journal of Pathology 2004 164 1 217 227 2-s2.0-1542574202 (Pubitemid 38364606)
121. Linja M. J., Savinainen K. J., Saramäki O. R., Tammela T. L. J., Vessella R. L., Visakorpi T., Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 2001 61 9 3550 3555 2-s2.0-0035328474 (Pubitemid 32694958)
122. Mostaghel E. A., Page S. T., Lin D. W., Fazli L., Coleman I. M., True L. D., Knudsen B., Hess D. L., Nelson C. C., Matsumoto A. M., Bremner W. J., Gleave M. E., Nelson P. S., Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research 2007 67 10 5033 5041 2-s2.0-34250331066 10.1158/0008-5472.CAN-06-3332 (Pubitemid 46910214)
123. Geller J., Albert J., Nachtsheim D., Loza D., Lippman S., Steroid levels in cancer of the prostate-markers of tumor differentiation and adequacy of anti-androgen therapy. Progress in Clinical and Biological Research 1979 33 103 111 2-s2.0-0018558912
124. Geller J., de la Vega D. J., Albert J. D., Nachtsheim D. A., Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer. Journal of Clinical Endocrinology and Metabolism 1984 58 1 36 40 2-s2.0-0021334278 (Pubitemid 14220514)
125. Nishiyama T., Hashimoto Y., Takahashi K., The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clinical Cancer Research 2004 10 21 7121 7126 2-s2.0-8444231965 10.1158/1078-0432.CCR-04-0913 (Pubitemid 39487695)
126. Locke J. A., Guns E. S., Lubik A. A., Adomat H. H., Hendy S. C., Wood C. A., Ettinger S. L., Gleave M. E., Nelson C. C., Androgen Levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 2008 68 15 6407 6415 2-s2.0-51049098138 10.1158/0008-5472.CAN-07-5997
127. Leon C. G., Locke J. A., Adomat H. H., Etinger S. L., Twiddy A. L., Neumann R. D., Nelson C. C., Guns E. S., Wasan K. M., Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. The Prostate 2010 70 4 390 400 2-s2.0-76149137405 10.1002/pros.21072
128. Tran C., Ouk S., Clegg N. J., Chen Y., Watson P. A., Arora V., Wongvipat J., Smith-Jones P. M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C. D., Higano C. S., Beer T. M., Hung D. T., Scher H. I., Jung M. E., Sawyers C. L., Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009 324 5928 787 790 2-s2.0-65649090203 10.1126/science.1168175
129. Watson P. A., Chen Y. F., Balbas M. D., Wongvipat J., Socci N. D., Viale A., Kim K., Sawyers C. L., Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America 2010 107 39 16759 16765 2-s2.0-78049280194 10.1073/pnas.1012443107
130. Clegg N. J., Wongvipat J., Joseph J. D., Tran C., Ouk S., Dilhas A., Grillot K., Bischoff E. D., Cai L., Aparicio A., Dorow S., Arora V., Shao G., Qian J., Zhao H., Yang G., Cao C., Sensintaffar J., Wasielewska T., Herbert M. R., Bonnefous C., Darimont B., Scher H. I., Smith-Jones P., Klang M., Smith N. D., Wu N., Ouerfelli O., Rix P. J., Heyman R. A., Jung M. E., Sawyers C. L., Hager J. H., ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research 2012 72 6 1494 1503 10.1158/0008-5472.CAN-11-3948
131. Attard G., Reid A. H. M., A'Hern R., Parker C., Oommen N. B., Folkerd E., Messiou C., Molife L. R., Maier G., Thompson E., Olmos D., Sinha R., Lee G., Dowsett M., Kaye S. B., Dearnaley D., Kheoh T., Molina A., De Bono J. S., Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of Clinical Oncology 2009 27 23 3742 3748 2-s2.0-68949094223 10.1200/JCO.2008.20.0642
132. Potter G. A., Elaine Barrie S., Jarman M., Rowlands M. G., Novel steroidal inhibitors of human cytochrome P45017 α (17 α -hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. Journal of Medicinal Chemistry 1995 38 13 2463 2471 2-s2.0-0029058770
133. Barrie S. E., Potter G. A., Goddard P. M., Haynes B. P., Dowsett M., Jarman M., Pharmacology of novel steroidal inhibitors of cytochrome p450(17 α) (17 α -hydroxylase/C17-20 lyase). Journal of Steroid Biochemistry and Molecular Biology 1994 50 5-6 267 273 2-s2.0-0028031372 10.1016/0960-0760(94)90131-7 (Pubitemid 24309119)
134. Fizazi K., Scher H. I., Molina A., Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study (vol 13, pg 983, 2012). The Lancet Oncology 2012 13 11 E464 E464
135. Ryan C. J., Smith M. R., de Bono J. S., Molina A., Logothetis C. J., de Souza P., Mainwaring P., Piulats J. M., Ng S., Carles J., Mulders P. F. A., Basch E., Small E. J., Saad F., Schrijvers D., van Poppel H., Mukherjee S. D., Suttmann H., Gerritsen W. R., Flaig T. W., George D. J., Yu E. Y., Efstathiou E., Pantuck A., Winquist E., Higano C. S., Taplin M.-E., Park Y., Kheoh T., Griffin T., Scher H. I., Rathkopf D. E., Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine 2013 368 2 138 148 10.1056/NEJMoa1209096
136. Vasaitis T., Belosay A., Schayowitz A., Khandelwal A., Chopra P., Gediya L. K., Guo Z., Fang H. B., Njar V. C. O., Brodie A. M. H., Androgen receptor inactivation contributes to antitumor efficacy of 17 α -hydroxylase/17,20-lyase inhibitor 3 β -hydroxy-17-(1H-benzimidazole-1-yl) androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics 2008 7 8 2348 2357 2-s2.0-53349101498 10.1158/1535-7163.MCT-08-0230
137. Attard G., Reid A. H. M., Yap T. A., Raynaud F., Dowsett M., Settatree S., Barrett M., Parker C., Martins V., Folkerd E., Clark J., Cooper C. S., Kaye S. B., Dearnaley D., Lee G., de Bono J. S., Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology 2008 26 28 4563 4571 2-s2.0-53749090666 10.1200/JCO.2007.15. 9749
138. Scher H. I., Fizazi K., Saad F., Taplin M.-E., Sternberg C. N., Miller K., De Wit R., Mulders P., Chi K. N., Shore N. D., Armstrong A. J., Flaig T. W., Fléchon A., Mainwaring P., Fleming M., Hainsworth J. D., Hirmand M., Selby B., Seely L., de Bono J. S., Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine 2012 367 13 1187 1197 10.1056/NEJMoa1207506
139. Basaria S., Muller D. C., Carducci M. A., Egan J., Dobs A. S., Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006 106 3 581 588 2-s2.0-31544440178 10.1002/cncr.21642 (Pubitemid 43157621)
140. Grundy S. M., Brewer H. B., Cleeman J. I., Smith S. C., Lenfant C., Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 2004 109 3 433 438 2-s2.0-0842277242 10.1161/01.CIR.0000111245.75752.C6 (Pubitemid 38133916)
141. Yialamas M. A., Dwyer A. A., Hanley E., Lee H., Pitteloud N., Hayes F. J., Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism 2007 92 11 4254 4259 2-s2.0-35948930594 10.1210/jc.2007-0454 (Pubitemid 350074740)
142. Yannucci J., Manola J., Garnick M. B., Bhat G., Bubley G. J., The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. Journal of Urology 2006 176 2 520 525 2-s2.0-33745240384 10.1016/j.juro.2006.03. 057 (Pubitemid 43927931)
143. Flanagan J., Gray P. K., Hahn N., Hayes J., Myers L. J., Carney-Doebbeling C., Sweeney C. J., Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Annals of Oncology 2011 22 4 801 807 2-s2.0-79953328519 10.1093/annonc/mdq443
144. Giganti M. G., Minella D., Testa B., Zenobi R., Biancolella M., Isidori A. M., Caprio M., Novelli G., Fabbri A., A pilot study on the transcriptional response of androgen- and insulin-related genes in peripheral blood mononuclear cells induced by testosterone administration in hypogonadal men. Journal of Biological Regulators and Homeostatic Agents 2011 25 2 291 294
145. Rohrmann S., Shiels M. S., Lopez D. S., Rifai N., Nelson W. G., Kanarek N., Guallar E., Menke A., Joshu C. E., Feinleib M., Sutcliffe S., Platz E. A., Body fatness and sex steroid hormone concentrations in US men: results from NHANES III. Cancer Causes and Control 2011 22 8 1141 1151 10.1007/s10552-011- 9790-z
146. Haffner S. M., Valdez R. A., Mykkanen L., Stern M. P., Katz M. S., Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994 43 5 599 603 2-s2.0-0028297129 10.1016/0026-0495(94)90202-X (Pubitemid 24145467)
147. Moriarty-Kelsey M., Harwood J. E. F., Travers S. H., Zeitler P. S., Nadeau K. J., Testosterone, obesity and insulin resistance in young males: evidence for an association between gonadal dysfunction and insulin resistance during puberty. Journal of Pediatric Endocrinology and Metabolism 2010 23 12 1281 1287 2-s2.0-79955486308 10.1515/jpem.2010.202
148. Wang C., Feng R., Sun D., Li Y., Bi X., Sun C., Metabolic profiling of urine in young obese men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC/Q-TOF MS). Journal of Chromatography B 2011 879 27 2871 2876 10.1016/j.jchromb.2011.08.014
149. Simon D., Preziosi P., Barrett-Connor E., Roger M., Saint-Paul M., Nahoul K., Papoz L., Interrelation between plasma testosterone and plasma insulin in healthy adult men: the telecom study. Diabetologia 1992 35 2 173 177 2-s2.0-0026547429
150. Pitteloud N., Mootha V. K., Dwyer A. A., Hardin M., Lee H., Eriksson K. F., Tripathy D., Yialamas M., Groop L., Elahi D., Hayes F. J., Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005 28 7 1636 1642 2-s2.0-24944450769 10.2337/diacare.28.7. 1636 (Pubitemid 41340902)
151. Rubinow K. B., Snyder C. N., Amory J. K., Hoofnagle A. N., Page S. T., Acute testosterone deprivation reduces insulin sensitivity in men. Clinical Endocrinology 2012 76 2 281 288 10.1111/j.1365-2265.2011.04189.x
152. Smith M. R., Lee H., Fallon M. A., Nathan D. M., Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008 71 2 318 322 2-s2.0-39549097295 10.1016/j.urology.2007.08.035 (Pubitemid 351282338)
153. Quinn D. I., Henshall S. M., Sutherland R. L., Molecular markers of prostate cancer outcome. European Journal of Cancer 2005 41 6 858 887 2-s2.0-16244376500 10.1016/j.ejca.2004.12.035 (Pubitemid 40461690)
154. Wang Y., Zhu Y., Zhang L., Tian W., Hua S., Zhao J., Zhang H., Xue F., Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. Cancer Letters 2012 322 2 223 231 10.1016/j.canlet.2012.03.026
155. Lubik A. A., Gunter J. H., Hendy S. C., Locke J. A., Adomat H. H., Thompson V., Herington A., Gleave M. E., Pollak M., Nelson C. C., Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Research 2011 71 17 5754 5764 10.1158/0008-5472.CAN-10-2470
156. Eichholz A., Ferraldeschi R., Attard G., de Bono J. S., Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Molecular and Cellular Endocrinology 2012 360 1-2 68 75 10.1016/j.mce.2011.09.038
157. Reis L. O., Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Medical Oncology 2012 29 3 1948 1955 2-s2.0-79957454981 10.1007/s12032-011-9991-z
158. Cohen B. L., Gomez P., Omori Y., Duncan R. C., Civantos F., Soloway M. S., Lokeshwar V. B., Lokeshwar B. L., Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence. International Journal of Cancer 2006 119 5 1082 1087 2-s2.0-33746329955 10.1002/ijc.21749 (Pubitemid 44116917)
159. Cao Z. X., Liu L. Z., Dixon D. A., Zheng J. Z., Chandran B., Jiang B. H., Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cellular Signalling 2007 19 7 1542 1553 2-s2.0-34249745222 10.1016/j.cellsig.2007.01.028 (Pubitemid 46824175)
160. Stoeltzing O., Liu W., Fan F., Wagner C., Stengel K., Somcio R. J., Reinmuth N., Parikh A. A., Hicklin D. J., Ellis L. M., Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system. Cancer Letters 2007 258 2 291 300 2-s2.0-36049034233 10.1016/j.canlet.2007.09.009 (Pubitemid 350101026)
161. Zoubeidi A., Zardan A., Beraldi E., Fazli L., Sowery R., Rennie P., Nelson C., Gleave M. E., Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research 2007 67 21 10455 10465 2-s2.0-35948950583 10.1158/0008-5472.CAN-07-2057 (Pubitemid 350070821)
162. Zoubeidi A., Zardan A., Wiedmann R. M., Locke J., Beraldi E., Fazli L., Gleave M. E., Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Research 2010 70 6 2307 2317 2-s2.0-77950267783 10.1158/0008-5472.CAN-09- 3252
163. Zhang J., Lei T., Chen X., Peng Y., Long H., Zhou L., Huang J., Chen Z., Long Q., Yang Z., Resistin up-regulates COX-2 expression via TAK1-IKK-NF- B signaling pathway. Inflammation 2010 33 1 25 33 2-s2.0-76149093530 10.1007/s10753-009-9155-x
164. Mullen E., O'Reilly E., Ohlendieck K., Skeletal muscle tissue from the Goto-Kakizaki rat model of type-2 diabetes exhibits increased levels of the small heat shock protein Hsp27. Molecular Medicine Reports 2011 4 2 229 236 2-s2.0-79551696981 10.3892/mmr.2011.437
165. Burut D. F. P., Borai A., Livingstone C., Ferns G., Serum heat shock protein 27 antigen and antibody levels appear to be related to the macrovascular complications associated with insulin resistance: a pilot study. Cell Stress and Chaperones 2010 15 4 379 386 2-s2.0-77955654012 10.1007/s12192-009-0152-7
166. Price R. S., Cavazos D. A., de Angel R. E., Hursting S. D., DeGraffenried L. A., Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer and Prostatic Diseases 2012 15 2 135 143 10.1038/pcan.2011.54
167. Gunter J. H., Lubik A. A., McKenzie I., Pollak M., Nelson C. C., The interactions between insulin and androgens in progression to castrate-resistant prostate cancer. Advances in Urology 2012 2012 11 248607 10.1155/2012/248607
168. Carver B. S., Chapinski C., Wongvipat J., Hieronymus H., Chen Y., Chandarlapaty S., Arora V. K., Le C., Koutcher J., Scher H., Scardino P. T., Rosen N., Sawyers C. L., Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate Ccancer. Cancer Cell 2011 19 5 575 586 2-s2.0-79955975429 10.1016/j.ccr.2011.04.008
169. Kaarbø M., Mikkelsen O. L., Malerød L., Qu S., Lobert V. H., Akgul G., Halvorsen T., Mælandsmo G. M., Saatcioglu F., PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cellular Oncology 2010 32 1-2 11 27 2-s2.0-77749242462 10.3233/CLO-2009-0487
170. Mulholland D. J., Tran L. M., Li Y., Cai H., Morim A., Wang S., Plaisier S., Garraway I. P., Huang J., Graeber T. G., Wu H., Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011 19 6 792 804 2-s2.0-79958764107 10.1016/j.ccr.2011.05.006
171. Xin L., Teitell M. A., Lawson D. A., Kwon A., Mellinghoff I. K., Witte O. N., Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proceedings of the National Academy of Sciences of the United States of America 2006 103 20 7789 7794 2-s2.0-33646739524 10.1073/pnas.0602567103
172. Carver B. S., Chapinski C., Wongvipat J., Hieronymus H., Chen Y., Chandarlapaty S., Arora V. K., Le C., Koutcher J., Scher H., Scardino P. T., Rosen N., Sawyers C. L., Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011 19 5 575 586 2-s2.0-79955975429 10.1016/j.ccr.2011.04.008
173. Malinowska K., Neuwirt H., Cavarretta I. T., Bektic J., Steiner H., Dietrich H., Moser P. L., Fuchs D., Hobisch A., Culig Z., Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocrine-Related Cancer 2009 16 1 155 169 2-s2.0-65549130575 10.1677/ERC-08-0174
174. Robinson D. R., Zylstra C. R., Williams B. O., Wnt signaling and prostate cancer. Current Drug Targets 2008 9 7 571 580 2-s2.0-52449124149 10.2174/138945008784911831
175. Seaton A., Scullin P., Maxwell P. J., Wilson C., Pettigrew J., Gallagher R., O'Sullivan J. M., Johnston P. G., Waugh D. J. J., Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 2008 29 6 1148 1156 2-s2.0-46949098184 10.1093/carcin/bgn109 (Pubitemid 351958693)
176. Frigo D. E., Howe M. K., Wittmann B. M., Brunner A. M., Cushman I., Wang Q., Brown M., Means A. R., McDonnell D. P., CaM kinase kinase β -mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Research 2011 71 2 528 537 2-s2.0-78751475852 10.1158/0008-5472.CAN-10-2581
177. Massie C. E., Lynch A., Ramos-Montoya A., Boren J., Stark R., Fazli L., Warren A., Scott H., Madhu B., Sharma N., Bon H., Zecchini V., Smith D. M., Denicola G. M., Mathews N., Osborne M., Hadfield J., MacArthur S., Adryan B., Lyons S. K., Brindle K. M., Griffiths J., Gleave M. E., Rennie P. S., Neal D. E., Mills I. G., The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. The EMBO Journal 2011 30 13 2719 2733 2-s2.0-79960071366 10.1038/emboj.2011.158
178. Shaw R. J., Bardeesy N., Manning B. D., Lopez L., Kosmatka M., DePinho R. A., Cantley L. C., The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004 6 1 91 99 2-s2.0-3142594193 10.1016/j.ccr.2004.06. 007 (Pubitemid 38903165)
179. Kodaman P. H., Duleba A. J., HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? Drugs 2008 68 13 1771 1785 2-s2.0-50249138738 10.2165/00003495-200868130-00001
180. Zheng X., Cui X. X., Gao Z., Zhao Y., Lin Y., Shih W. J., Huang M. T., Liu Y., Rabson A., Reddy B., Yang C. S., Conney A. H., Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prevention Research 2010 3 1 114 124 2-s2.0-77649195951 10.1158/1940-6207.CAPR-09-0059
181. Swinnen J. V., Roskams T., Joniau S., van Poppel H., Oyen R., Baert L., Heyns W., Verhoeven G., Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. International Journal of Cancer 2002 98 1 19 22 2-s2.0-0036497907 10.1002/ijc.10127 (Pubitemid 34113412)
182. Rashid M. H., Chaudhary U. B., Intermittent androgen deprivation therapy for prostate cancer. Oncologist 2004 9 3 295 301 2-s2.0-2942584859 10.1634/theoncologist.9-3-295 (Pubitemid 38756877)
183. Scher H. I., Sawyers C. L., Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology 2005 23 32 8253 8261 2-s2.0-33644675811 10.1200/JCO.2005.03.4777 (Pubitemid 46211563)
184. So A., Gleave M., Hurtado-Col A., Nelson C., Mechanisms of the development of androgen independence in prostate cancer. World Journal of Urology 2005 23 1 1 9 2-s2.0-15844429706 10.1007/s00345-004-0473-1 (Pubitemid 40425164)
185. Stanbrough M., Bubley G. J., Ross K., Golub T. R., Rubin M. A., Penning T. M., Febbo P. G., Balk S. P., Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 2006 66 5 2815 2825 2-s2.0-33645056171 10.1158/0008-5472.CAN-05-4000
186. Redig A. J., Munshi H. G., Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy. The American Journal of Medicine 2010 123 1 87.e1 87.e6 2-s2.0-72649099139 10.1016/j.amjmed.2009.06.022